These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32536690)

  • 1. Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia.
    Alruwetei AM; Bendak K; Yadav BD; Carol H; Evans K; Mayoh C; Sutton R; Marshall GM; Lock RB
    Br J Cancer; 2020 Sep; 123(5):742-751. PubMed ID: 32536690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.
    Szymanska B; Wilczynska-Kalak U; Kang MH; Liem NL; Carol H; Boehm I; Groepper D; Reynolds CP; Stewart CF; Lock RB
    PLoS One; 2012; 7(3):e33894. PubMed ID: 22479469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
    Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
    Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse.
    Hijiya N; Gajjar A; Zhang Z; Sandlund JT; Ribeiro RC; Rubnitz JE; Jeha S; Liu W; Cheng C; Raimondi SC; Behm FG; Rivera GK; Relling MV; Pui CH
    Leukemia; 2004 Oct; 18(10):1581-6. PubMed ID: 15356657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
    Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
    Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
    Lopez-Millan B; Sanchéz-Martínez D; Roca-Ho H; Gutiérrez-Agüera F; Molina O; Diaz de la Guardia R; Torres-Ruiz R; Fuster JL; Ballerini P; Suessbier U; Nombela-Arrieta C; Bueno C; Menéndez P
    Leukemia; 2019 Jul; 33(7):1557-1569. PubMed ID: 30635633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.
    Kang MH; Kang YH; Szymanska B; Wilczynska-Kalak U; Sheard MA; Harned TM; Lock RB; Reynolds CP
    Blood; 2007 Sep; 110(6):2057-66. PubMed ID: 17536015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of reinduction chemotherapy in bone marrow relapse of childhood acute lymphoblastic leukemia].
    Sato Y; Ito R; Saito T; Suto Y; Tateoka N; Onodera N; Ikeda Y; Ito E; Miyano T; Tachibana N
    Rinsho Ketsueki; 1989 Nov; 30(11):1923-30. PubMed ID: 2607611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
    Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
    Thomson B; Park JR; Felgenhauer J; Meshinchi S; Holcenberg J; Geyer JR; Avramis V; Douglas JG; Loken MR; Hawkins DS
    Pediatr Blood Cancer; 2004 Oct; 43(5):571-9. PubMed ID: 15382275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
    August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study.
    Lawson SE; Harrison G; Richards S; Oakhill A; Stevens R; Eden OB; Darbyshire PJ
    Br J Haematol; 2000 Mar; 108(3):531-43. PubMed ID: 10759711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol.
    Steinherz PG; Redner A; Steinherz L; Meyers P; Tan C; Heller G
    Cancer; 1993 Nov; 72(10):3120-30. PubMed ID: 8221579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow necrosis and thrombotic complications in childhood acute lymphoblastic leukemia.
    Eguiguren JM; Pui CH
    Med Pediatr Oncol; 1992; 20(1):58-60. PubMed ID: 1727213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse.
    Lock RB; Liem N; Farnsworth ML; Milross CG; Xue C; Tajbakhsh M; Haber M; Norris MD; Marshall GM; Rice AM
    Blood; 2002 Jun; 99(11):4100-8. PubMed ID: 12010813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts.
    Jones L; McCalmont H; Evans K; Mayoh C; Kurmasheva RT; Billups CA; Houghton PJ; Smith MA; Lock RB
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27765. PubMed ID: 31012549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts.
    Randall J; Evans K; Watts B; Smith CM; Hughes K; Earley EJ; Erickson SW; Pachter JA; Teicher BA; Smith MA; Lock RB
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30398. PubMed ID: 37140091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
    Hijiya N; Stewart CF; Zhou Y; Campana D; Coustan-Smith E; Rivera GK; Relling MV; Pui CH; Gajjar A
    Cancer; 2008 May; 112(9):1983-91. PubMed ID: 18318429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.
    Koh KN; Im HJ; Kim H; Kang HJ; Park KD; Shin HY; Ahn HS; Lee JW; Yoo KH; Sung KW; Koo HH; Lim YT; Park JE; Park BK; Park HJ; Seo JJ
    J Korean Med Sci; 2017 Apr; 32(4):642-649. PubMed ID: 28244291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.